Estudios activos


GEMCAD 1601: “Preoperative Induction Therapy with 12 weeks of panitumumab in combination with mFOLFOX-6 in an enriched population (Quadruple Wild-Type) of patients with mrT3 rectal cancer of the middle third with clear mesorectal fascia” PIER Trial. Coordinador Dr. C. Fernández Martos

GEMCAD 1602 – AVEVAC: “Phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated MSS metastatic colorectal cancer patients”. 9 centros participantes. En proceso de firmas de contratos.

GEMCAD 1603: “Phase II study to evaluate the efficacy and safety of FOLFIRI + panitumumab as first-line treatment in elderly patients with unresectable wild type RAS/BRAF metastatic colorectal cancer: the OPALO study”. Coordinador Dr. J. Feliu

GEMCAD 1402 – RIA: “Phase II randomized trial of induction FOLFOX vs FOLFOX plus aflibercet followed by CRT in high risk rectal adenocarcinoma”: Finalizado el reclutamiento. Pacientes reclutado 180. En fase de seguimiento. Primer análisis de endpoint primario último trimestre 2017.

GEMCAD 1701 “Randomized phase II study to evaluate the efficacy of second-line FOLFIRI+ panitumumab in patients with wild type RAS metastatic colorectal cancer who have received first line FOLFOX + panitumumab”. Coordinador Dr. J. Aparicio